| 1 |
35225058 | PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy. | 2022 Jan-Dec |
9 |
| 2 |
35565437 | Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer. | 2022 May 6 |
1 |
| 3 |
32656671 | Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. | 2021 May |
2 |
| 4 |
33670162 | PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. | 2021 Feb 11 |
3 |
| 5 |
30767115 | Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on Local Recurrence. | 2020 Apr |
1 |
| 6 |
32388585 | PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions. | 2020 Oct |
2 |
| 7 |
32429929 | Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. | 2020 May 19 |
2 |
| 8 |
32493336 | Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy. | 2020 Jun 3 |
3 |
| 9 |
33110814 | Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting. | 2020 Aug |
3 |
| 10 |
30064200 | Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer. | 2019 Apr |
2 |
| 11 |
30085020 | Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients. | 2019 Mar 1 |
1 |
| 12 |
31723167 | Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. | 2019 Nov 13 |
1 |
| 13 |
31897310 | The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy. | 2019 Nov |
2 |
| 14 |
28422766 | An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. | 2018 Oct |
1 |
| 15 |
29615063 | Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. | 2018 Apr 4 |
1 |
| 16 |
30314669 | Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. | 2018 Dec |
2 |
| 17 |
29190949 | Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. | 2017 Nov 3 |
1 |
| 18 |
27015293 | Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. | 2016 Jun |
1 |
| 19 |
27581532 | Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. | 2016 Nov |
6 |
| 20 |
28723397 | Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. | 2016 Feb |
5 |